

Cite this: *RSC Adv.*, 2017, 7, 56457Received 29th September 2017
Accepted 8th December 2017

DOI: 10.1039/c7ra10775g

rsc.li/rsc-advances

Asymmetric synthesis of 2,3-disubstituted indolines via an organocatalytic intramolecular Michael addition†

Jusung Lee, Kwang Min Ko and Sung-Gon Kim *

An asymmetric synthesis of 2,3-disubstituted indolines has been developed via an organocatalytic intramolecular Michael addition. When a primary amine derived from cinchona alkaloid was used as the catalyst, the intramolecular cyclization reaction of (*E*)-3-(2-(2-oxopropylamino)aryl)-1-arylprop-2-en-1-ones afforded the corresponding *cis*-2,3-disubstituted indoline derivatives with high yields, moderate diastereoselectivities, and excellent enantioselectivities (up to 2.7 : 1 dr and 99% ee). Moreover, the catalytic reaction of (*E*)-3-(2-(2-oxopropylamino)aryl)-1-alkylprop-2-en-1-ones afforded *trans*-2,3-disubstituted indolines in high yields and with good-to-excellent diastereo- and enantioselectivities (up to 20 : 1 dr and 99% ee).

Optically active indolines are structurally essential elements in biologically active natural alkaloids and chiral pharmaceuticals.¹ Among various indolines, chiral 2,3-disubstituted indolines are significant building blocks in both synthetic and medicinal chemistry because they are present in numerous natural products and pharmaceuticals including (–)-strychnine, aspidospermidine, WAY-163909, and (–)-physostigmine, as shown in Fig. 1.² They have two chiral centers leading to four possible diastereomers, each of which can exhibit significantly different chemical and biological activities. Therefore, it is challenging and interesting to develop novel synthetic methodologies for constructing enantioenriched 2,3-disubstituted indoline derivatives in synthetic organic chemistry.

Consequently, diverse strategies have been developed for the synthesis of enantioenriched indolines.³ Among these, the most powerful tool for the asymmetric synthesis of 2,3-disubstituted indolines is the catalytic hydrogenation of substituted indole derivatives.⁴ Although asymmetric hydrogenation is one of the most straightforward methods in terms of simplicity and atom efficiency, this transformation affords only *cis*-2,3-disubstituted indolines. Catalytic kinetic resolution is also used to obtain such chiral indolines.⁵ Recently, some significant syntheses of optically active indolines have been achieved using asymmetric intramolecular cyclization reactions such as electrophilic cyclization.⁶ The benefit of these reactions is the easy introduction of various functional groups at the 2- and 3-positions of indoline. Kündig and co-workers reported that the reaction of *N*-aryl, *N*-

branched alkyl carbamates with a Pd-catalyst bearing chiral *N*-heterocyclic carbene ligand, giving enantioenriched 2,3-disubstituted indolines.^{6c} Xiao and co-workers developed an innovative cycloaddition strategy for the enantioselective synthesis of *trans*-2,3-disubstituted indolines, involving the Pd-catalyzed decarboxylation-cycloaddition reaction of vinyl benzoxazinones with sulfur ylides.^{6b} More recently, Buchwald and co-workers reported an efficient Cu-H-catalyzed strategy using 2-alkenylimine precursors obtained from alkenylanilines and aromatic aldehydes for the highly diastereo- and enantioselective synthesis of *cis*-2,3-disubstituted indolines.^{6a} However, to the best of our knowledge, the synthesis of chiral 2,3-disubstituted indolines by asymmetric cycloaddition using organocatalyst has not been reported, even though asymmetric organocatalysis has significantly progressed over the past decade.^{7,8}

Within the framework of our program devoted to the development of stereoselective cascade reactions of *o*-aminophenyl





Fig. 1 Representative chiral 2,3-disubstituted indoline derivatives.

Department of Chemistry, Kyonggi University, 154-42, Gwanggyosan-ro, Yeongtong-gu, Suwon 16227, Republic of Korea. E-mail: sgkim123@kyonggi.ac.kr

† Electronic supplementary information (ESI) available. CCDC 1527668. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c7ra10775g



Table 2 Optimization of the reaction conditions^a

Entry	Additive	Solvent	Time (h)	Yield ^b (%)	<i>cis/trans</i> ^c	ee ^{d,e} (%)
1	AcOH	Toluene	120	85	41 : 59	88/85
2	CF ₃ CO ₂ H	Toluene	72	91	59 : 41	91/88
3	CCl ₃ CO ₂ H	Toluene	48	88	63 : 37	93/88
4	PhCO ₂ H	Toluene	24	95	59 : 41	94/88
5	4-NO ₂ BzOH	Toluene	6	85	40 : 60	93/89
6	2-NO ₂ BzOH	Toluene	8	94	64 : 36	96/88
7	2-NO ₂ BzOH	CH ₂ Cl ₂	10	98	56 : 44	95/90
8	2-NO ₂ BzOH	ClCH ₂ CH ₂ Cl	8	97	51 : 49	95/90
9	2-NO ₂ BzOH	CHCl ₃	6	96	60 : 40	96/87
10	2-NO ₂ BzOH	EtOAc	4	96	60 : 40	96/90
11	2-NO ₂ BzOH	CH ₃ CN	96	41	23 : 77	51/36
12	2-NO ₂ BzOH	THF	96	73	52 : 48	89/68
13	2-NO ₂ BzOH	MeOH	96	50	20 : 80	48/45
14 ^f	2-NO ₂ BzOH	EtOAc	24	98	63 : 37	98/94
15 ^g	2-NO ₂ BzOH	EtOAc	28	97	62 : 38	96/89

^a Unless otherwise specified, the reactions were performed with 0.1 mmol of **1a**, catalyst **IIIId** (10 mol%), and additive (20 mol%) in solvent (0.2 M).

^b Isolated yield after chromatographic purification. ^c Determined by ¹H NMR analysis. ^d The ee values were determined by chiral HPLC analysis. ^e ee values *cis/trans* diastereomers. ^f Reaction performed at 0 °C. ^g Reaction performed with 10 mol% 2-NO₂BzOH at 0 °C.


CHCl₃, and EtOAc, the reaction smoothly proceeded and completed within 10 h, affording the corresponding product **2a** in high yields and with excellent enantioselectivities for both diastereomers (Table 2, entries 6–10). In CH₃CN, THF and MeOH, the reaction was completed in a longer time than in other solvents with moderate yields and enantioselectivities, even though a high enantioselectivity was observed for the major diastereomer in THF (Table 2, entries 11–13). Although a low diastereoselectivity was observed in EtOAc, both the diastereomers were obtained in the highest yields and enantioselectivities (Table 2, entry 10). Therefore, EtOAc was selected as the most suitable solvent for this asymmetric intramolecular Michael addition. A lower reaction temperature provided a better stereocontrol. The desired product was achieved in an excellent yield and with enantioselectivities (98% ee *cis* isomer; 94% ee *trans* isomer) and a moderate diastereoselectivity (*cis/trans*, 63 : 37) (Table 2, entry 14). In addition, when the amount of 2-nitrobenzoic acid was reduced from 20 mol% to 10 mol%, the enantioselectivity decreased (Table 2, entry 14).

With the optimized reaction conditions in hand (1 equiv. of **1**, 10 mol% catalyst **IIIId**, and 20 mol% 2-nitrobenzoic acid in EtOAc at 0 °C), the substrate scope of the reaction was investigated, and the results are summarized in Table 3. This transformation has a broad substrate scope. The reactions of all the substrates smoothly afforded the corresponding indolines in moderate-to-high yields (62–97%) and with excellent enantioselectivities (93–99% ee) for the major diastereomer in all the

cases except *p*-Me-substituted substrate **1m**. Gratifyingly, the electronic nature of the R¹ group slightly affected the reaction efficiencies with regard to enantioselectivities and yields. Both electron-withdrawing (Table 3, entries 2–4) and electron-donating (Table 3, entries 5 and 6) groups were well tolerated; the obtained diastereoselectivities were still low in all the cases. For the R² group, the reactions proceeded well with electron-withdrawing substituents (Table 3, entries 7–12) and electron-donating substituents (Table 3, entries 12–14). Notably, a substrate bearing an *ortho*- and *para*-substituted halogen group on the phenyl R² group afforded the corresponding product with a higher diastereoselectivity than the other substrates. A substrate bearing both *ortho*-substituted chloro group provided *trans*-2,3-disubstituted indoline **2j** in the major diastereomer (*cis/trans*, 33 : 67) (Table 3, entry 10). Moreover, a heteroaromatic group was introduced at the R² position; the reaction proceeded rapidly, affording the corresponding products **2o** and **2p** in high yields and with good enantiocontrol (over 91% ee, Table 3, entries 15 and 16).


To evaluate the practical applications of this methodology, a gram-scale reaction using the standard conditions was conducted; product **2a** was obtained without any significant changes in the yield or stereoselectivity (Scheme 2). The absolute configuration of product *cis*-**2d** was determined by X-ray crystallographic analysis and found to be 2*S*,3*R*.¹⁴ The configurations of the other products were assigned by analogy.



Table 3 Substrate scope of the organocatalytic asymmetric intramolecular Michael addition^a


Entry	R ¹	R ²	Time (h)	2	Yield ^b (%)	cis/trans ^c	ee ^{d,e} (%)
1	H	Ph	28	2a	97	63 : 37	98/94
2	4-Cl	Ph	36	2b	96	58 : 42	95/93
3	5-Cl	Ph	48	2c	88	58 : 42	99/95
4	4-Br	Ph	48	2d	97	56 : 44	99/95
5	4-Me	Ph	56	2e	91	60 : 40	99/93
6	4,5-MeO	Ph	72	2f	62	58 : 42	95/97
7	H	<i>p</i> -ClC ₆ H ₄	36	2g	86	61 : 39	92/76
8	H	<i>m</i> -ClC ₆ H ₄	56	2h	93	51 : 49	92/90
9	H	<i>o</i> -ClC ₆ H ₄	48	2i	96	73 : 27	94/92
10	H	2,6-Cl ₂ C ₆ H ₃	96	2j	83	33 : 67	91/90
11	H	<i>p</i> -BrC ₆ H ₄	48	2k	82	70 : 30	98/94
12	H	<i>p</i> -FC ₆ H ₄	36	2l	95	65 : 35	95/86
13	H	<i>p</i> -MeC ₆ H ₄	36	2m	85	54 : 46	90/84
14	H	<i>p</i> -MeOC ₆ H ₄	48	2n	91	55 : 45	96/89
15	H	2-Furanyl	36	2o	92	47 : 53	92/91
16	H	2-Thienyl	24	2p	86	43 : 57	94/94

^a All reactions were performed with 0.1 mmol of **1**, catalyst **III d** (10 mol%), and 2-NO₂BzOH (20 mol%) in EtOAc (0.2 M) at 0 °C. ^b Isolated yield after chromatographic purification. ^c Determined by ¹H NMR analysis. ^d The ee values were determined by chiral HPLC analysis. ^e ee values *cis/trans* diastereomers.

Scheme 2 Gram-scale synthesis of indoline **2a** and X-ray crystal structure of *cis*-**2d**.


Furthermore, the reactions of (*E*)-3-(2-(2-oxopropylamino)aryl)-1-alkylprop-2-en-1-ones bearing an alkyl group at the R² position, such as methyl, cyclopropyl and *t*-butyl, smoothly afforded the corresponding 2,3-disubstituted indolines in high yields and with excellent enantioselectivities (Table 4, entries 1–

3). To our delight, *t*-butyl α,β -unsaturated ketone provided the desired *trans*-2,3-disubstituted indoline **4c** with an excellent diastereomeric ratio (*trans/cis*, 13 : 1) and enantioselectivity (98% ee; Table 4, entry 3).¹⁵ Encouraged by the excellent results obtained using *t*-butyl α,β -unsaturated ketone, the scope of our strategy was further extended. No obvious impact was observed on either the reaction efficiency or stereoselectivity, regardless of the electronic nature, bulkiness, or position of the substituent on the benzene ring of (*E*)-3-(2-(2-oxopropylamino)aryl)-1-*t*-butylprop-2-en-1-ones. Both electron-withdrawing groups (Table 4, entries 4–6) and electron-donating groups (Table 4, entries 7 and 8) were well tolerated, and all the products were obtained in good yields and with excellent diastereoselectivities (*trans/cis*, 13 : 1 to >25 : 1) and enantioselectivities (93–99% ee).

On the basis of our experimental results, a plausible transition state for this asymmetric Michael reaction is shown in Scheme 3. The Si-face attack of *anti*-enamine to the Re-face of *t*-butyl α,β -unsaturated ketone led to the formation of the *S,S*-configured *trans*-indoline **4c**.


To further demonstrate the synthetic utility of this methodology, we have illustrated a representative procedure to convert the enantioenriched indoline product into the corresponding alkenyl ester **5** (Scheme 4). The reaction of *trans*-**4c** with methyl(triphenylphosphoranylidene)acetate provided Wittig product **5** in moderate yield without affecting the enantioselectivity.




Table 4 Distereo- and enantioselective synthesis of *trans*-2,3-disubstituted indoline^a


Entry	R ¹	R ²	Time (h)	4	Yield ^b (%)	<i>trans/cis</i> ^c	ee ^d (%)
1	H	Me	72	4a	65	1 : 1.5	84/87
2	H	Cyclopropyl	48	4b	93	4 : 1	94
3	H	<i>t</i> -Bu	18	4c	98	13 : 1	98
4	4-Cl	<i>t</i> -Bu	12	4d	97	13 : 1	95
5	5-Cl	<i>t</i> -Bu	48	4e	78	>25 : 1	93
6	4-Br	<i>t</i> -Bu	12	4f	92	15 : 1	98
7	4-Me	<i>t</i> -Bu	18	4g	98	20 : 1	99
8	4,5-MeO	<i>t</i> -Bu	18	4h	85	>25 : 1	99

^a Unless otherwise specified, the reactions were performed with 0.1 mmol of **3**, catalyst **IIIId** (10 mol%), and 2-NO₂BzOH (20 mol%) in EtOAc (0.2 M) at 0 °C. ^b Isolated yield after chromatographic purification. ^c Determined by ¹H NMR analysis. ^d The ee values were determined by chiral HPLC analysis.



Scheme 3 Plausible transition state.

Scheme 4 The synthetic transformation of indoline *trans*-4c.

Conclusions

In conclusion, we have developed an efficient method for the asymmetric synthesis of 2,3-disubstituted indolines through an organocatalytic intramolecular Michael addition. The reaction of (*E*)-3-(2-(2-oxopropylamino)aryl)-1-arylprop-2-en-1-ones afforded the corresponding *cis*-2,3-disubstituted indoline derivatives in high yields and with moderate diastereoselectivities and excellent enantioselectivities (up to 2.7 : 1 dr and 99% ee) using a primary amine derived from a cinchona alkaloid as the catalyst. Moreover, the catalytic reaction of (*E*)-3-

(2-(2-oxopropylamino)aryl)-1-alkylprop-2-en-1-ones helped to develop an unprecedented approach for the synthesis of chiral *trans*-2,3-disubstituted indolines in high yields and with good-to-excellent diastereo- and enantioselectivities (up to >25 : 1 dr, and 99% ee).

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This research was supported by the Nanomaterial Technology Development Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (NRF-2012M3A7B4049645) and the Basic Science Research Program through NRF funded by the Ministry of Education (NRF-2016R1D1A1A09916621).

Notes and references

- For recent reviews, see: (a) E. Fattorusso and O. Tagliatela-Scafati, *Modern Alkaloids*, Wiley-VCH, Weinheim, 2008; (b) G. M. Cragg, D. G. I. Kingston and D. J. Newman, *Anticancer Agents from Natural Products*, CRC, Boca Raton, FL, 2012; (c) D. Crich and A. Banerjee, *Acc. Chem. Res.*, 2007, **40**, 151; (d) D. L. Boger, C. W. Boyce, R. M. Garbaccio and J. A. Goldberg, *Chem. Rev.*, 1997, **97**, 787.
- (a) T. Bui, S. Syed and C. F. Barbas III, *J. Am. Chem. Soc.*, 2009, **131**, 8758; (b) H. Zhang, J. Boonsombat and A. Padwa, *Org. Lett.*, 2007, **9**, 279; (c) K. L. Marquis, A. L. Sabb, S. F. Logue, J. A. Brennan, M. J. Piesla, T. A. Comery, S. M. Grauer, C. R. Ashby Jr, H. Q. Nguyen, L. A. Dawson, J. E. Barret,



- G. Stack, H. Y. Meltzer, B. L. Harrison and S. Rosenzweig-Lipson, *J. Pharmacol. Exp. Ther.*, 2007, **320**, 486; (d) R. Iyengar, K. Schildknecht, M. Morton and J. Aube, *J. Org. Chem.*, 2005, **70**, 10645.
- 3 (a) D. Zhang, H. Song and Y. Qin, *Acc. Chem. Res.*, 2011, **44**, 447; (b) D. Liu, G. Zhao and L. Xiang, *Eur. J. Inorg. Chem.*, 2010, 3975, and references therein.
- 4 For recent selected examples, see: (a) Z. Yang, F. Chen, Y. He, N. Yang and Q.-H. Fan, *Angew. Chem., Int. Ed.*, 2016, **55**, 13863; (b) Y.-C. Zhang, J.-J. Zhao, F. Jiang, S.-B. Sun and F. Shi, *Angew. Chem., Int. Ed.*, 2014, **53**, 13912; (c) C. Romano, M. Jia, M. Monari, E. Manoni and M. Bandini, *Angew. Chem., Int. Ed.*, 2014, **53**, 13854; (d) L. Chen, C. Wang, L. Zhou and J. Sun, *Adv. Synth. Catal.*, 2014, **356**, 2224; (e) Y. Duan, M.-W. Chen, Q.-A. Chen, C.-B. Yu and Y.-G. Zhou, *Org. Biomol. Chem.*, 2012, **10**, 1235; (f) Y.-C. Xiao, C. Wang, Y. Yao, J. Sun and Y.-C. Chen, *Angew. Chem., Int. Ed.*, 2011, **50**, 10661; (g) Y. Duan, M.-W. Chen, Z.-S. Ye, D.-S. Wang, Q.-A. Chen and Y.-G. Zhou, *Chem.-Eur. J.*, 2011, **17**, 7193; (h) M.-W. Chen, C.-B. Yu, Y. Duan and G.-F. Jiang, *Chem. Sci.*, 2011, **2**, 803.
- 5 (a) K. Saito, Y. Shibata, M. Yamanaka and T. Akiyama, *J. Am. Chem. Soc.*, 2013, **135**, 11740; (b) M. Lopez-Iglesias, E. Busto, V. Gotor and V. Gotor-Fernández, *J. Org. Chem.*, 2012, **77**, 8049; (c) X. L. Hou and B. H. Zheng, *Org. Lett.*, 2009, **11**, 789; (d) F. O. Arp and G. C. Fu, *J. Am. Chem. Soc.*, 2006, **128**, 14264; (e) V. Gotor-Fernández, P. Fernández-Torres and V. Gotor, *Tetrahedron: Asymmetry*, 2006, **17**, 2558.
- 6 (a) E. Ascic and S. L. Buchwald, *J. Am. Chem. Soc.*, 2015, **137**, 4666; (b) T.-R. Li, F. Tan, L.-Q. Lu, Y. Wei, Y.-N. Wang, Y.-Y. Liu, Q.-Q. Yang, J.-R. Chen, D.-Q. Shi and W.-J. Xiao, *Nat. Commun.*, 2014, **5**, 5500; (c) D. Katayev, M. Nakanishi, T. Bürgi and E. T. Kündig, *Chem. Sci.*, 2012, **3**, 1422; (d) K. H. Kang, J. Do and Y. S. Park, *J. Org. Chem.*, 2012, **77**, 808; (e) J. L. García Ruano, A. Parra, V. Marcos, C. del Pozo, S. Catalán, S. Monteagudo, S. Fustero and A. Poveda, *J. Am. Chem. Soc.*, 2009, **131**, 9432; (f) J. L. García Ruano, J. Alemán, S. Catalán, V. Marcos, S. Monteagudo, A. Parra, C. del Pozo and S. Fustero, *Angew. Chem., Int. Ed.*, 2008, **47**, 7941.
- 7 For examples of organocatalytic asymmetric syntheses of 2-substituted indolines *via* cycloaddition, see: (a) R. Miyaji, K. Asano and S. Matsubara, *Org. Lett.*, 2013, **15**, 3658; (b) S. Fustero, C. del Pozo, C. Mulet, R. Lazaro and M. Sánchez-Roselló, *Chem.-Eur. J.*, 2011, **17**, 14267; (c) S. Fustero, J. Moscardó, D. Jiménez, M. D. Pérez-Carrión, M. Sánchez-Roselló and C. del Pozo, *Chem.-Eur. J.*, 2008, **14**, 9868; (d) E. C. Carlson, L. K. Rathbone, H. Yang, N. D. Collett and R. G. Carter, *J. Org. Chem.*, 2008, **73**, 5155.
- 8 For selected reviews on organocatalysis, see: (a) A. Moyano and R. Rios, *Chem. Rev.*, 2011, **111**, 4703; (b) H. Pellissier, *Recent Developments in Asymmetric Organocatalysis*, RSC, Cambridge, 2010; (c) S. Bertelsen and K. A. Jørgensen, *Chem. Soc. Rev.*, 2009, **38**, 2178; (d) A. Dondoni and A. Massi, *Angew. Chem., Int. Ed. Engl.*, 2008, **47**, 4638; (e) P. I. Dalko, *Enantioselective Organocatalysis*, Wiley-VCH, Weinheim, 2007.
- 9 (a) Y. Lee, S. Heo and S.-G. Kim, *Adv. Synth. Catal.*, 2015, **357**, 1545; (b) H. Kim and S.-G. Kim, *Tetrahedron Lett.*, 2015, **56**, 4819; (c) M. Yu and S.-G. Kim, *Tetrahedron Lett.*, 2015, **56**, 4159; (d) A. Kim, C. Kim and S.-G. Kim, *Bull. Korean Chem. Soc.*, 2015, **36**, 417; (e) Y. Lee and S.-G. Kim, *J. Org. Chem.*, 2014, **79**, 8234; (f) K.-T. Kang and S.-G. Kim, *Synthesis*, 2014, **46**, 3365; (g) S. Kim, K.-T. Kang and S.-G. Kim, *Tetrahedron*, 2014, **70**, 5114; (h) C. Kim and S.-G. Kim, *Tetrahedron: Asymmetry*, 2014, **25**, 1376; (i) S. Heo, S. Kim and S.-G. Kim, *Tetrahedron Lett.*, 2013, **54**, 4978.
- 10 M. Yu and S.-G. Kim, *Tetrahedron Lett.*, 2015, **56**, 7034.
- 11 (a) S. Sakamoto, T. Inokuma and Y. Takemoto, *Org. Lett.*, 2011, **13**, 6374; (b) T. Okino, Y. Hoashi and Y. Takemoto, *J. Am. Chem. Soc.*, 2003, **125**, 12672.
- 12 For selected reviews on bifunctional cinchona thiourea catalysis, see: (a) B. Han, J.-L. Li, Y.-C. Xiao, S.-L. Zhou and Y.-C. Chen, *Curr. Org. Chem.*, 2011, **15**, 4128; (b) Y. Takemoto, *Chem. Pharm. Bull.*, 2010, **58**, 593; (c) C. E. Song, *Cinchona Alkaloids in Synthesis & Catalysis*, Wiley-VCH, Weinheim, 2009; (d) S. J. Connon, *Chem. Commun.*, 2008, 2499.
- 13 For selected reviews on primary amine catalysis, see: (a) P. Melchiorre, *Angew. Chem., Int. Ed.*, 2012, **51**, 9748; (b) L.-W. Xu, J. Luo and Y. Lu, *Chem. Commun.*, 2009, 1807; (c) F. Peng and Z. Shao, *J. Mol. Catal. A: Chem.*, 2008, **285**, 1.
- 14 CCDC 1527668 (2d) contains the supplementary crystallographic data for this paper.†
- 15 The relative stereochemistry of compound 4 (*trans*-isomer) was established by the distinguished chemical shift in ¹H NMR of the *trans*-isomer and by NOESY.

